KR20190060888A - 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열 - Google Patents

재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열 Download PDF

Info

Publication number
KR20190060888A
KR20190060888A KR1020197015057A KR20197015057A KR20190060888A KR 20190060888 A KR20190060888 A KR 20190060888A KR 1020197015057 A KR1020197015057 A KR 1020197015057A KR 20197015057 A KR20197015057 A KR 20197015057A KR 20190060888 A KR20190060888 A KR 20190060888A
Authority
KR
South Korea
Prior art keywords
protein
signal sequence
bip
dna
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197015057A
Other languages
English (en)
Korean (ko)
Inventor
헝 도
Original Assignee
아미쿠스 세라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아미쿠스 세라퓨틱스, 인코포레이티드 filed Critical 아미쿠스 세라퓨틱스, 인코포레이티드
Publication of KR20190060888A publication Critical patent/KR20190060888A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0002—Antibodies with enzymatic activity, e.g. abzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/10—Energy storage using batteries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197015057A 2010-11-22 2011-11-22 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열 Ceased KR20190060888A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41592610P 2010-11-22 2010-11-22
US61/415,926 2010-11-22
PCT/US2011/061862 WO2012071422A2 (en) 2010-11-22 2011-11-22 Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137016110A Division KR101984318B1 (ko) 2010-11-22 2011-11-22 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열

Publications (1)

Publication Number Publication Date
KR20190060888A true KR20190060888A (ko) 2019-06-03

Family

ID=46146394

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197015057A Ceased KR20190060888A (ko) 2010-11-22 2011-11-22 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열
KR1020137016110A Active KR101984318B1 (ko) 2010-11-22 2011-11-22 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020137016110A Active KR101984318B1 (ko) 2010-11-22 2011-11-22 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열

Country Status (19)

Country Link
US (1) US9279007B2 (cg-RX-API-DMAC7.html)
EP (2) EP3461905B1 (cg-RX-API-DMAC7.html)
JP (1) JP2014503198A (cg-RX-API-DMAC7.html)
KR (2) KR20190060888A (cg-RX-API-DMAC7.html)
CN (1) CN103328649B (cg-RX-API-DMAC7.html)
BR (1) BR112013012671B1 (cg-RX-API-DMAC7.html)
CA (1) CA2818689C (cg-RX-API-DMAC7.html)
CY (1) CY1121049T1 (cg-RX-API-DMAC7.html)
DK (2) DK3461905T3 (cg-RX-API-DMAC7.html)
ES (2) ES2829199T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20181315T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039070T2 (cg-RX-API-DMAC7.html)
LT (1) LT2643468T (cg-RX-API-DMAC7.html)
PL (1) PL2643468T3 (cg-RX-API-DMAC7.html)
PT (1) PT2643468T (cg-RX-API-DMAC7.html)
RS (1) RS57601B1 (cg-RX-API-DMAC7.html)
SI (1) SI2643468T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800466T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012071422A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20192243T1 (hr) * 2014-07-03 2020-03-06 F. Hoffmann - La Roche Ag Polipeptidni ekspresijski sustavi
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN111936624A (zh) * 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
TW202344691A (zh) 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7577650B2 (ja) 2018-10-10 2024-11-05 アミカス セラピューティックス インコーポレイテッド ジスルフィド結合により安定したポリペプチド組成物及びその使用方法
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
JP2022514863A (ja) * 2018-12-19 2022-02-16 ヴェルサメブ アーゲー タンパク質をコードするｒｎａ
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
US20220193261A1 (en) * 2019-04-30 2022-06-23 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of pompe disease
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021087282A1 (en) * 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods
CN112342247B (zh) * 2020-11-10 2022-03-11 江苏科技大学 一种提高家蚕细胞表达外源蛋白分泌率的方法
WO2022119890A1 (en) 2020-12-01 2022-06-09 The Trustees Of The University Of Pennsylvania Compositions and uses thereof for treatment of angelman syndrome
US20250034533A1 (en) 2021-11-12 2025-01-30 Amicus Therapeutics, Inc. Compositions And Methods For Treating Mucopolysaccharidosis IIIA
WO2025264978A2 (en) 2024-06-20 2025-12-26 Amicus Therapeutics, Inc. Recombinant alpha-galactosidase a proteins and gene therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000031113A1 (en) * 1998-11-24 2000-06-02 Bristol-Myers Squibb Company INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN
EP1689766B1 (en) * 2003-11-06 2012-04-25 Danisco US Inc. Expression in filamentous fungi of protease inhibitors and variants thereof
ATE474917T1 (de) * 2006-04-11 2010-08-15 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide

Also Published As

Publication number Publication date
KR20130121878A (ko) 2013-11-06
CN103328649A (zh) 2013-09-25
ES2829199T3 (es) 2021-05-31
DK3461905T3 (da) 2020-11-02
CA2818689A1 (en) 2012-05-31
CN103328649B (zh) 2016-06-22
EP2643468B1 (en) 2018-07-04
EP3461905B1 (en) 2020-08-05
SMT201800466T1 (it) 2018-11-09
KR101984318B1 (ko) 2019-05-31
EP2643468A2 (en) 2013-10-02
LT2643468T (lt) 2018-09-10
US9279007B2 (en) 2016-03-08
RS57601B1 (sr) 2018-11-30
ES2687415T3 (es) 2018-10-25
JP2014503198A (ja) 2014-02-13
EP3461905A1 (en) 2019-04-03
CY1121049T1 (el) 2019-12-11
WO2012071422A2 (en) 2012-05-31
BR112013012671A2 (pt) 2016-10-11
EP2643468A4 (en) 2014-12-24
US20140045216A1 (en) 2014-02-13
PT2643468T (pt) 2018-10-11
PL2643468T3 (pl) 2018-11-30
HRP20181315T1 (hr) 2018-10-19
SI2643468T1 (sl) 2018-10-30
HUE039070T2 (hu) 2018-12-28
WO2012071422A3 (en) 2012-08-02
CA2818689C (en) 2021-09-21
BR112013012671B1 (pt) 2022-03-03
DK2643468T3 (en) 2018-09-24

Similar Documents

Publication Publication Date Title
KR101984318B1 (ko) 재조합 효소 및 다른 단백질의 단백질 발현 및 분비를 개선시키기 위한 신규 신호 서열
Jiang et al. Integral membrane protein sorting to vacuoles in plant cells: evidence for two pathways
Saunders et al. Secretion of human serum albumin from Bacillus subtilis
Kollmann et al. Identification of novel lysosomal matrix proteins by proteome analysis
Rothblatt et al. Secretion in yeast: structural features influencing the post‐translational translocation of prepro‐alpha‐factor in vitro.
Kermode Mechanisms of intracellular protein transport and targeting in plant cells
Van Loon et al. Transport of proteins to the mitochondrial intermembrane space: the ‘matrix‐targeting’and the ‘sorting’domains in the cytochrome c1 presequence.
Johnson et al. Post-translational processing of surfactant protein-C proprotein: targeting motifs in the NH2-terminal flanking domain are cleaved in late compartments
KR20210032972A (ko) 전사인자를 사용하여 단백질 발현을 증가시키는 수단 및 방법
Ng et al. Protein translocation across the endoplasmic reticulum
RU2429243C2 (ru) Производство белков
CN117120618A (zh) 用于增加蛋白质分泌的信号肽
Shrimal et al. Asparagine-linked glycosylation is not directly coupled to protein translocation across the endoplasmic reticulum in Saccharomyces cerevisiae
WO1989010971A1 (en) Vector for secretion of proteins directly into periplasm or culture medium
Holden et al. Secretion of cartilage oligomeric matrix protein is affected by the signal peptide
JPH0272892A (ja) 蛋白質の製造方法
Schuster et al. Protein expression in yeast; comparison of two expression strategies regarding protein maturation
HK40006980A (en) Novel signal sequences to improve protein expression and secretion of recombinant enzymes and other proteins
Kaderbhai et al. A directed evolution strategy for optimized export of recombinant proteins reveals critical determinants for preprotein discharge
Eskridge et al. The NH2 terminus of preproinsulin directs the translocation and glycosylation of a bacterial cytoplasmic protein by mammalian microsomal membranes.
HK1189913B (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
HK1189913A (en) Novel signal sequences to improve protein expressions and secretion of recombinant enzymes and other proteins
US20210388046A1 (en) Chimeric signal peptides for protein production
Dhamne et al. Lentiviral vector platform for improved erythropoietin expression concomitant with shRNA mediated host cell elastase down regulation
KR20130075737A (ko) 기능성 아시알로당단백질 수용체를 발현하는 유전자 변형 세포주의 시알릴화 당단백질 생산에의 이용

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190524

Application number text: 1020137016110

Filing date: 20130621

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190621

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190805

Patent event code: PE09021S01D

AMND Amendment
AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200204

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190805

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200204

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20191105

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191104

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200409

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200402

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20200204

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191105

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191104

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190805

X601 Decision of rejection after re-examination